---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-032300"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:30:01.207918+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KalVista FY2023 net loss $92.9M; sebetralstat Phase 3 enrollment complete

## Summary
- Phase 3 KONFIDENT trial achieved target enrollment (114 patients); data readout expected Q4 2023; NDA planned H1 2024.
- Net loss FY2023 $92.9M ($3.33/share) vs $82.3M ($3.36/share); no revenue.
- R&D expenses $80.3M (FY2023) vs $70.2M; G&A $30.6M vs $26.4M.
- Cash, equivalents and marketable securities $149.4M; funded into 2025 after $58M registered direct offering.
- Promoted Benjamin Palleiko to President; appointed Brian Pereira as Chairman.

## SEC filing metadata
- accession: 0000950170-23-032300
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/0000950170-23-032300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/kalv-20230707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-032300
- JSON: https://secwatch.observer/filing/0000950170-23-032300.json
- Plain text: https://secwatch.observer/filing/0000950170-23-032300.txt

## Key facts
- Earnings Releases
  KalVista Pharmaceuticals, Inc. reported fiscal year ended April 30, 2023 results: revenue No revenue was recognized, net income $92.9 million, EPS $(3.33) per weighted average basic and diluted share.
  - Period: fiscal year ended April 30, 2023
  - Revenue: No revenue was recognized
  - Net income: $92.9 million
  - EPS: $(3.33) per weighted average basic and diluted share
  - Result: reported results
  source text: Net loss was $92.9 million, or $(3.33) per weighted average basic and diluted share for the fiscal year ended April 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/0000950170-23-032300-index.htm
- Earnings Releases
  KalVista Pharmaceuticals, Inc. reported three months ended April 30, 2023 results: revenue No revenue was recognized, net income $26.3 million, EPS $(0.77) per weighted average basic and diluted share.
  - Period: three months ended April 30, 2023
  - Revenue: No revenue was recognized
  - Net income: $26.3 million
  - EPS: $(0.77) per weighted average basic and diluted share
  - Result: reported results
  source text: Net loss was $26.3 million, or $(0.77) per weighted average basic and diluted share, for the three months ended April 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/0000950170-23-032300-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.